ClinicalTrials.gg
CompletedNCT06688123Updated Jun 4, 2026

Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects

A Phase 2 interventional study of SHR-3167 and SHR-3167 in Type 2 Diabetes, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
275
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. — 8 open to participants now, 11 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
18th of 81
275 · median 80
Started
2025
with 5 others
Phase 2
15 of 81
1 open now
Registered
67th of 81
by date

Among the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., this one is the 18th largest by enrollment, is one of 6 that started in 2025, is one of 15 in phase 2, and was the 67th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

8 of the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of SHR-3167 compared with insulin glargine after treatment in insulin naïve subjects with type 2 diabetes treated with metformin alone or in combination with SGLT2 subjects.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written .
  2. Diagnosed with type 2 diabetes mellitus ≥ 6 months prior to the day of screening.
  3. A stable dose of metformin alone or in combination with a stable dose of a SGLT2 inhibitor for 3 months prior to screening.
  4. (BMI): 18.5\~35.0 kg/m2.
  5. of 7.5%\~10.0% as assessed by the local laboratory.
  6. Insulin naïve.
  7. Female subjects and partners of male subjects who are of , have no fertility plan and agree to take highly effective measures within 6 months after signing the informed consent form to the last dose, and have no plans to donate eggs/sperm; Female subjects of childbearing potential have a negative pregnancy test during the screening period and are not lactating.

Exclusion criteria

Exclusion Criteria:

  1. (ECG) results show abnormalities that may affect the safety of the subject.
  2. Poor blood pressure control at screening.
  3. Diagnosis or suspicion of type 1 diabetes mellitus, latent diabetes mellitus in adult (LADA),other special types of diabetes or secondary diabetes mellitus.
  4. ≥1 episode of severe hypoglycemia or asymptomatic hypoglycemia within 6 months prior to screening, or recurrent hypoglycemic events within 1 month prior to screening.
  5. History of diabetic ketoacidosis or hyperosmolar hyperglycemic state due to hyperglycemia within 6 months prior to screening.
  6. Presence of acute or chronic hepatitis, cirrhosis, or other serious liver disease other than non-alcoholic fatty liver disease.
  7. Those who have a history of severe cardiovascular and cerebrovascular diseases within 6 months before screening.
  8. or history of malignancy within 5 years prior to screening.
  9. Received any diabetes mellitus or weight-loss medication outside the inclusion criteria within 3 months prior to screening.
  10. Participation in a clinical trial of any drug or medical device within 3 months prior to screening.
  11. Any other condition judged by the investigator to be likely to affect the subject's safety or interfere with the evaluation of trial results.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
275 participants (actual)

Study arms

  • Experimental
    SHR-3167 group A

    Drug: SHR-3167

  • Experimental
    SHR-3167 group B

    Drug: SHR-3167

  • Active comparator
    Insulin glargine group

    Drug: Insulin glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline to week 20 in HbA1c (HemoglobinA1c)

    Change from baseline in HbA1c after 20 weeks of treatment.

    Time frame: Week 0 to week 20.

Secondary outcomes

  1. Percentage of participants achieving HbA1c<7.0%

    Time frame: Week 0 to week 20.

  2. Change from baseline to week 20 in fasting plasma glucose (FPG)

    Time frame: Week 0 to week 20.

  3. Change from baseline to week 20 in self-measured blood glucose (SMBG) before breakfast

    Time frame: Week 0 to week 20.

  4. Number of adverse events (AEs) during the trial

    Time frame: Week 0 to week 24.

07

Study locations

2 sites
  • Jiangsu Provincial People's Hospital
    Nanjing, Jiangsu 210029, China
  • Shanghai Sixth People's Hospital
    Shanghai, Shanghai Municipality 200233, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Apr 2026, 15 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 15 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 14, 2024
StartActual
Jan 8, 2025
Primary completionActual
Apr 22, 2026
CompletionActual
Apr 22, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06688123
Responsible party
Sponsor
First posted
Nov 14, 2024
Start date
Jan 8, 2025
Primary completion
Apr 22, 2026
Completion
Apr 22, 2026
Last update
Jun 4, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-3167

Start the discussion